BRPI0915517B8 - método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica - Google Patents
método para a produção de um conjugado de vi, conjugado, e, composição farmacêuticaInfo
- Publication number
- BRPI0915517B8 BRPI0915517B8 BRPI0915517A BRPI0915517A BRPI0915517B8 BR PI0915517 B8 BRPI0915517 B8 BR PI0915517B8 BR PI0915517 A BRPI0915517 A BR PI0915517A BR PI0915517 A BRPI0915517 A BR PI0915517A BR PI0915517 B8 BRPI0915517 B8 BR PI0915517B8
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- producing
- pharmaceutical composition
- crm197
- derivatized
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 102000016607 Diphtheria Toxin Human genes 0.000 abstract 1
- 108010053187 Diphtheria Toxin Proteins 0.000 abstract 1
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001718 carbodiimides Chemical class 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 229960000814 tetanus toxoid Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
sacarídeos vi conjugados. dois conjugados de vi foram preparados por síntese mediada por carbodiimida, com o uso de ácido adípico dihidrazida derivatizada crm197 (uma variante não tóxica de toxina diftérica) e toxóide tetânico, como proteínas veículoas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0810894.6A GB0810894D0 (en) | 2008-06-13 | 2008-06-13 | Conjugated saccharide |
| GB0810894.6 | 2008-06-13 | ||
| PCT/IB2009/006285 WO2009150543A2 (en) | 2008-06-13 | 2009-06-12 | Conjugated vi saccharides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0915517A2 BRPI0915517A2 (pt) | 2017-06-20 |
| BRPI0915517B1 BRPI0915517B1 (pt) | 2020-10-06 |
| BRPI0915517B8 true BRPI0915517B8 (pt) | 2021-05-25 |
Family
ID=39672273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0915517A BRPI0915517B8 (pt) | 2008-06-13 | 2009-06-12 | método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20110142876A1 (pt) |
| EP (1) | EP2303333B1 (pt) |
| CN (1) | CN102089009B (pt) |
| AU (1) | AU2009259017B2 (pt) |
| BR (1) | BRPI0915517B8 (pt) |
| CA (1) | CA2727565C (pt) |
| CY (1) | CY1116379T1 (pt) |
| DK (1) | DK2303333T3 (pt) |
| ES (1) | ES2537019T3 (pt) |
| GB (1) | GB0810894D0 (pt) |
| HR (1) | HRP20150527T1 (pt) |
| HU (1) | HUE025512T2 (pt) |
| NZ (1) | NZ590089A (pt) |
| PL (1) | PL2303333T3 (pt) |
| PT (1) | PT2303333E (pt) |
| SI (1) | SI2303333T1 (pt) |
| WO (1) | WO2009150543A2 (pt) |
| ZA (1) | ZA201009304B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102120761B (zh) * | 2010-12-24 | 2013-02-06 | 新疆维吾尔自治区畜牧科学院兽医研究所 | 一种无荚膜型金黄色葡萄球菌胞外多糖-蛋白质偶联物的制备方法 |
| EP2755683B1 (en) | 2011-09-14 | 2019-04-03 | GlaxoSmithKline Biologicals SA | Methods for making saccharide-protein glycoconjugates |
| MX365726B (es) * | 2013-08-24 | 2019-06-11 | Bharat Biotech Int Ltd | Vacuna bacteriana y metodos para la fabricacion de la misma. |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| US20190134177A1 (en) * | 2016-04-25 | 2019-05-09 | National Institute Of Immunology | Conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate |
| CN109890413B (zh) | 2016-09-02 | 2024-04-16 | 赛诺菲巴斯德股份有限公司 | 脑膜炎奈瑟氏菌疫苗 |
| BR112022008761A2 (pt) | 2019-11-22 | 2022-07-26 | Glaxosmithkline Biologicals Sa | Dosagem e administração de uma vacina de glicoconjugado de sacarídeo |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL102687A (en) * | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| US5738855A (en) | 1994-10-17 | 1998-04-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide |
| AU2000278267A1 (en) | 2000-09-01 | 2002-03-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Vibrio cholerae o139 conjugate vaccines |
| WO2003094961A1 (en) * | 2002-05-09 | 2003-11-20 | Massimo Porro | Improved polysaccharide and glycoconjugate vaccines_____________ |
| US8048432B2 (en) * | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
| SI2097102T1 (sl) * | 2006-09-07 | 2012-09-28 | Glaxosmithkline Biolog Sa | Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus |
| GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
-
2008
- 2008-06-13 GB GBGB0810894.6A patent/GB0810894D0/en not_active Ceased
-
2009
- 2009-06-12 HU HUE09762071A patent/HUE025512T2/hu unknown
- 2009-06-12 CA CA2727565A patent/CA2727565C/en active Active
- 2009-06-12 DK DK09762071.0T patent/DK2303333T3/da active
- 2009-06-12 SI SI200931193T patent/SI2303333T1/sl unknown
- 2009-06-12 EP EP09762071.0A patent/EP2303333B1/en active Active
- 2009-06-12 ES ES09762071.0T patent/ES2537019T3/es active Active
- 2009-06-12 BR BRPI0915517A patent/BRPI0915517B8/pt active IP Right Grant
- 2009-06-12 NZ NZ590089A patent/NZ590089A/xx unknown
- 2009-06-12 US US12/997,411 patent/US20110142876A1/en not_active Abandoned
- 2009-06-12 PL PL09762071T patent/PL2303333T3/pl unknown
- 2009-06-12 CN CN2009801278952A patent/CN102089009B/zh active Active
- 2009-06-12 WO PCT/IB2009/006285 patent/WO2009150543A2/en not_active Ceased
- 2009-06-12 HR HRP20150527TT patent/HRP20150527T1/hr unknown
- 2009-06-12 PT PT97620710T patent/PT2303333E/pt unknown
- 2009-06-12 AU AU2009259017A patent/AU2009259017B2/en active Active
-
2010
- 2010-12-23 ZA ZA2010/09304A patent/ZA201009304B/en unknown
-
2012
- 2012-10-26 US US13/661,409 patent/US9475846B2/en active Active
-
2015
- 2015-05-11 CY CY20151100416T patent/CY1116379T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20150527T1 (xx) | 2015-06-19 |
| US20130142822A1 (en) | 2013-06-06 |
| EP2303333B1 (en) | 2015-02-18 |
| HUE025512T2 (hu) | 2016-05-30 |
| AU2009259017B2 (en) | 2014-12-11 |
| AU2009259017A1 (en) | 2009-12-17 |
| DK2303333T3 (da) | 2015-05-26 |
| BRPI0915517B1 (pt) | 2020-10-06 |
| US9475846B2 (en) | 2016-10-25 |
| EP2303333A2 (en) | 2011-04-06 |
| CY1116379T1 (el) | 2017-02-08 |
| GB0810894D0 (en) | 2008-07-23 |
| US20110142876A1 (en) | 2011-06-16 |
| PT2303333E (pt) | 2015-06-08 |
| ES2537019T3 (es) | 2015-06-01 |
| PL2303333T3 (pl) | 2015-11-30 |
| NZ590089A (en) | 2012-12-21 |
| CN102089009A (zh) | 2011-06-08 |
| WO2009150543A2 (en) | 2009-12-17 |
| ZA201009304B (en) | 2012-08-29 |
| BRPI0915517A2 (pt) | 2017-06-20 |
| CA2727565C (en) | 2017-01-10 |
| WO2009150543A3 (en) | 2010-05-06 |
| SI2303333T1 (sl) | 2015-06-30 |
| CA2727565A1 (en) | 2009-12-17 |
| CN102089009B (zh) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110065A1 (es) | Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8 | |
| MX354103B (es) | Composicion inmunogenica. | |
| AR060187A1 (es) | Composicion inmunogenica | |
| CL2016000566A1 (es) | Método para para preparar una composición inmunogénica multivalente que comprende 13 conjugados de un serotipo diferente de streptococcus pneumoniae, donde cada uno de los conjugados contiene un polisacárido capsular diferente conjugado a la proteína portadora crm197. div. sol. madre n° 200600802 e hija cl 201702206. | |
| CY1116901T1 (el) | Εμβολιο που περιλαμβανει προϊοντα συζευξης καψικου πολυσακχαριδιου streptococcus pneumoniae | |
| PE20120582A1 (es) | Conjugados de insulina cristalina | |
| AR116043A2 (es) | Composición de vacuna conjugada de polisacárido-proteína neumocócica 15-valente | |
| BRPI0611872B8 (pt) | reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica | |
| GB201101665D0 (en) | Immunogenic compositions | |
| BR112013023015A8 (pt) | conjugado de amatoxina e seu uso, composição farmacêutica e seu uso, molécula de conjugação de amatoxina, método para a síntese de um conjungado de amatoxina. | |
| NZ600039A (en) | Biocompatible biodegradable fumagillin analog conjugates | |
| BR112012000569B8 (pt) | composição compreendendo um conjugado de benzoato-hidrocodona (bz-hc) e composições para administração oral e intravenosa compreendendo o mesmo | |
| AR058592A1 (es) | Vacuna | |
| RU2014151567A (ru) | Конъюгат менингококка серогруппы х | |
| EA200702577A1 (ru) | Способ изготовления вакцин | |
| NZ588884A (en) | Cross-linkers and their uses | |
| BR112016004023A2 (pt) | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto | |
| MY188455A (en) | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates | |
| EA200801935A1 (ru) | Конъюгатные вакцины | |
| WO2008106186A3 (en) | Activated polyoxazolines and compositions comprising the same | |
| CL2012000744A1 (es) | Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende. | |
| AR092897A1 (es) | Composiciones inmunogenicas | |
| CY1116379T1 (el) | Συζευγμενοι vi σακχαριτες | |
| WO2012106251A3 (en) | Pertussis vaccine | |
| BRPI0917819B8 (pt) | compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), A61P 43/00 (2006.01) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25A | Requested transfer of rights approved |
Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) |